CytoSorbents Corporation

About CytoSorbents Corporation

CytoSorbents is a company focused on advancing blood purification technologies to address critical health challenges. Their mission is to save lives by providing innovative solutions that restore balance and control damage in patients, offering technology that goes beyond traditional dialysis.

Products & Services

CytoSorb:A blood purification therapy that restores balance to prevent damage. Not available in the US.

PuriFi:A standalone platform tailored to CytoSorb. Not available in the US.

ECOS:Works with ex vivo organ perfusion to reduce inflammation. Not available in the US.

VetResQ:A solution leveraging CytoSorb technology for pet health emergencies. Available only in the US.

DrugSorb:A product in the pipeline focused on specific therapeutic applications.

HemoDefend:A product in the pipeline aimed at blood purification innovations.

Specialties

Blood Purification Hemoadsorption Critical Care Cardiovascular Therapy Liver Therapy Kidney Therapy Polymer Bead Technology

Funding History

Debug: View Raw Funding Data

#	Type	Amount Fields	Date Fields	Investors
1	RT: Tax Credit Sale T: - FT: Tax Credit Sale	A: 1700000 MR: - FA: approximately $1.7 million FAN: 1700000	D: 2025-04-21 FD: 2025-04-21	1 investors
2	RT: Rights Offering Warrant Exercise T: - FT: Rights Offering Warrant Exercise	A: 1600000 MR: - FA: $1.6 million FAN: 1600000	D: 2025-02-25 FD: 2025-02-25	1 investors
3	RT: Rights Offering T: - FT: Rights Offering	A: 6250000 MR: - FA: $6.25 Million FAN: 6250000	D: 2025-01-13 FD: 2025-01-13	2 investors
4	RT: Rights Offering T: - FT: Rights Offering	A: 1 MR: - FA: 1.00 per Unit FAN: 1	D: 2024-12-23 FD: 2024-12-23	-
5	RT: Rights Offering T: - FT: Rights Offering	A: 6250000 MR: - FA: Up to $6,250,000 FAN: 6250000	D: 2024-12-09 FD: 2024-12-09	-
6	RT: Debt T: - FT: Debt	A: 20000000 MR: - FA: $20 million FAN: 20000000	D: 2024-07-02 FD: 2024-07-02	3 investors
7	RT: Registered Direct Offering T: - FT: Registered Direct Offering	A: 10285010 MR: - FA: $10,285,009.70 FAN: 10285010	D: 2023-12-13 FD: 2023-12-13	3 investors

Tax Credit Sale Latest

2025-04-21

$1.7M

1 investor (Pro only)

Rights Offering Warrant Exercise 2025-02-25

$1.6M

Rights Offering 2025-01-13

$6.2M

View 6 more funding rounds with Pro

Unlock Full Funding History

Growth Metrics

+45%

Employee Growth

YoY

3.2x

Funding Growth

Last Round

12

Markets

Operating

10K+

Customers

Active

View 3 more growth metrics with Pro

Unlock All Metrics

Mock Up

Team & Leadership

M

Michael Bator

Chairman of the Board

P

Phillip P. Chan

Chief Executive Officer

E

Edward R. Jones

MD, MBA, Clinical Professor of Medicine, Temple University Hospital

A

Alan D. Sobel

MS, CPA, Managing Member, Sobel & Co., LLC

J

Jiny Kim

Vice President, Smart Implants, Technology & Data Solutions, Zimmer Biomet

A

Arjan Ruhrparwar

Professor

View 29 more team members with Pro

Unlock Full Team Directory

Recent News